

Annex C: Summary view of Gavi 6.0 mission and strategy performance indicators

	Strategic objectives	Strategy impact/outcome indicators	Targets	Accountability
Mission 2030	To save lives and protect people's health by increasing equitable and sustainable use of vaccines	M1 Under-five child mortality reduction M2 Future deaths averted (disaggregated for climate-sensitive diseases) * M3 Future DALYs averted M4 Reduction in zero-dose children * M5 Children immunised M6 Economic benefits unlocked		Alliance
Strategic Goal 1	A Strengthen countries' prioritisation and optimisation of vaccine programmes, appropriate to their context	1a % countries conducting prioritisation and optimisation process ^		Alliance
	B Support countries to introduce and scale up vaccines for prevention of endemic, epidemic and pandemic diseases including beyond infancy	1b.1 Breadth of protection * 1b.2 Inactivated polio vaccine 2 nd dose (IPV2) coverage ^		
	C Ensure equitable and timely access to mechanisms to respond to outbreaks, epidemics, and pandemics	1c % outbreaks with timely detection and response *		
Strategic Goal 2	A Enable countries to extend immunisation to zero-dose children and missed communities, integrated with primary health care, including through addressing gender-related barriers and building resilient demand	2a Geographic equity * (TBD)		Alliance
	B Ensure all children are fully immunised by maintaining and strengthening routine immunisation with vaccines required through second year of life	2b.1 Diphtheria tetanus pertussis vaccine 3 rd dose (DTP3) coverage *† 2b.2 Measles containing vaccine 1 st dose (MCV1) coverage * 2b.3 Measles containing vaccine 2 nd dose (MCV2) coverage *†		
	C Support countries to adapt systems to routinely deliver vaccines to populations outside early childhood through targeted and catalytic interventions	2c Human papillomavirus vaccine (complete) coverage *†		
Strategic Goal 3	A Strengthen regional, national and subnational political and social commitment to immunisation, including through increased domestic public resources	3a % countries fulfilling cofinancing commitment		Alliance
	B Ensure sustainable transition through stronger capacity of eligible countries to maintain immunisation performance	3b % countries in preparatory or accelerated transition with positive trends in DTP1, DTP3, and MCV2 ^		
	C Engage self-financing countries to maintain performance and catalyse critical vaccine introductions	3c Number of new vaccine introductions in the catalytic phase *		
Strategic Goal 4	A Drive healthy vaccine markets for Gavi-supported and self-financing countries, including acceleration of access to new high-impact, affordable vaccines and delivery innovations	4a.1 Number of markets with acceptable levels of supply security ^ 4a.2 Weighted average price of Gavi-supported vaccines & related products ^		Alliance
	B Enhance regional vaccine supply security, in support of regional manufacturing expansion ambitions	4b Progress in African regional vaccine manufacturing ^		
	C Develop sustainable markets for vaccines against outbreak, epidemic, and pandemic-prone diseases	4c Available supply for vaccines against OEP diseases ^		

* Linked to IA2030
† SDG indicator for immunisation
^ New from Gavi 5.0/5.1